Results 211 to 220 of about 1,804,540 (378)

Radiographic and pathologic response of myxoid liposarcoma treated with preoperative radiotherapy. [PDF]

Radiol Oncol
Gao RW, Jebastin JA, Wenger DE, Harmsen WS, Folpe AL, Haddock MG, Petersen IA, Ahmed SK.   +7 more
europepmc   +1 more source

A nucleotide‐independent, pan‐RAS‐targeted DARPin elicits anti‐tumor activity in a multimodal manner

Molecular Oncology, EarlyView.
We report a Designed Ankyrin Repeat Protein that binds and inhibits RAS proteins, which serve as central cell signaling hubs and are essential for the progression of many cancers. Its unique feature is that it does not discriminate between different RAS isoforms or mutations and is capable of binding to RAS in both its active (GTP‐bound) and inactive ...
Jonas N. Kapp, Wouter P. R. Verdurmen, Jonas V. Schaefer, Kari Kopra, Gabriela Nagy‐Davidescu, Elodie Richard, Marie‐Julie Nokin, Patrick Ernst, Rastislav Tamaskovic, Martin Schwill, Ralph Degen, Claudia Scholl, David Santamaria, Andreas Plückthun   +13 more
wiley   +1 more source

Klotho and phosphate are modulators of pathologic uremic cardiac remodeling.

Journal of the American Society of Nephrology, 2015
M. Hu, Mingjun Shi, Han Jun Cho, B. Adams-Huet, Jean Paek, K. Hill, J. Shelton, A. Amaral, C. Faul, M. Taniguchi, M. Wolf, M. Brand, Masaya Takahashi, M. Kuro-o, Joseph A. Hill, O. Moe   +15 more
semanticscholar   +1 more source

PCED1A serves as a potential biomarker for diagnosis and prognosis in colorectal cancer. [PDF]

Discov Oncol
Wang C, Zhang D, Huang Y.
europepmc   +1 more source

Therapeutic applications of a novel humanized monoclonal antibody targeting chemokine receptor CCR9 in pancreatic cancer

Molecular Oncology, EarlyView.
C–C chemokine receptor type 9 (CCR9) is an immune checkpoint in pancreatic ductal adenocarcinoma (PDAC). Novel anti‐CCR9 antibody SRB2 was evaluated in combination with cytotoxic chemotherapy in PDAC cells, patient‐derived organoids, patient‐derived xenografts, and humanized mouse models.
Hannah G. McDonald, Anna M. Reagan, Charles J. Bailey, Mei Gao, Muqiang Gao, Angelica L. Solomon, Michael J. Cavnar, Prakash K. Pandalai, Mautin T. Barry‐Hundeyin, Megan M. Harper, Justin A. Rueckert, Ángela Turrero, Araceli Tobio, Anxo Vidal, Daniel Roca‐Lema, Elia Álvarez‐Coiradas, Pablo Garrido, Laureano Simón, Joseph Kim   +18 more
wiley   +1 more source

THE RELATION OF HEMATIN TO PATHOLOGICAL PIGMENT FORMATION [PDF]

, 1911
Wade H. Brown
openalex   +1 more source

Unraveling LINE‐1 retrotransposition in head and neck squamous cell carcinoma

Molecular Oncology, EarlyView.
The novel RetroTest method allows the detection of L1 activation in clinical samples with low DNA input, providing global L1 activity and the identification of the L1 source element. We applied RetroTest to a real‐world cohort of HNSCC patients where we reported an early L1 activation, with more than 60% of T1 patients showing L1 activity.
Jenifer Brea‐Iglesias, Ana Oitabén, Sonia Zumalave, Bernardo Rodriguez‐Martin, María Gallardo‐Gómez, Martín Santamarina, Ana Pequeño‐Valtierra, Laura Juaneda‐Magdalena, Ramón García‐Escudero, José Luis López‐Cedrún, Máximo Fraga, José M. C. Tubio, Mónica Martínez‐Fernández   +12 more
wiley   +1 more source

Pathologic function and therapeutic potential of exosomes in cardiovascular disease.

Biochimica et Biophysica Acta, 2015
Shaina Ailawadi, Xiaohong Wang, Haitao Gu, G. Fan   +3 more
semanticscholar   +1 more source

Concerns regarding Palee et al. and reasserting the underlying mechanism of action in percutaneous tenotomy. [PDF]

Interv Pain Med
Sussman WI, Hall M, Boettcher BJ.
europepmc   +1 more source

Micro-Chemistry of Poisons, including Their Physiological, Pathological, and Legal Relations; with an Appendix on the Detection and Microscopic Discrimination of Blood; adapted to the Use of the Medical Jurist, Physician, and General Chemist.

, 1885

openalex   +2 more sources